Table 1.

Baseline characteristics of participants who completed a clinical trial assessing the effect of increasing dialysate magnesium concentration on serum calcification propensity measured by T50

DemographicsTotal, n=57Standard Dialysate Magnesium, n=29High Dialysate Magnesium, n=28
Sex, men/women35/2219/1016/12
Age, yr73 (63–80)73 (54–78)73 (63–82)
Body mass index, m2/kg25.3 (21.9–29.7)26.2 (22.9–30.4)24.3 (21.0–28.2)
White race (%)55 (97)29 (100)26 (93)
African race (%)2 (3)0 (0)2 (7)
Cause of ESKD (%)
 Diabetes mellitus15 (26)10 (34)5 (18)
 Hypertension14 (25)8 (28)6 (21)
 Glomerular diseases4 (7)1 (3)3 (11)
 Polycystic kidney disease8 (14)4 (14)4 (14)
 Interstitial nephritis1 (2)0 (0)1 (4)
 Other8 (14)4 (14)4 (14)
 Unknown7 (12)2 (7)5 (18)
Comorbidities (%)
 Diabetes mellitus type 12 (4)2 (7)0 (0)
 Diabetes mellitus type 216 (28)10 (34)6 (21)
 Hypertension45 (79)25 (86)20 (71)
 Dyslipidemia26 (46)12 (41)14 (50)
 Coronary artery disease20 (35)12 (41)8 (29)
 Heart failure10 (18)4 (14)6 (21)
 Peripheral artery disease10 (18)7 (24)3 (11)
 Previous stroke11 (19)2 (7)9 (32)
 Inflammatory disease6 (11)1 (3)5 (18)
 Chronic obstructive pulmonary disease8 (14)1 (3)7 (25)
Dialysis modality (%)
 Hemodialysis29 (51)18 (62)11 (39)
 Hemodiafiltration28 (49)11 (38)17 (61)
Dialysis access (%)
 Catheter16 (28)10 (34)6 (21)
 Fistula41 (72)19 (66)22 (79)
Dialysis filter (%)
 Polyflux 140H1 (2)0 (0)1 (4)
 Polyflux 170H30 (52)15 (52)15 (54)
 Polyflux 210H26 (46)14 (48)12 (43)
Dialysis vintage, mo32 (18–70)30 (13–59)39 (21–99)
Dialysis session length, min210 (210–240)210 (210–240)210 (206–240)
Weekly dialysis time, min630 (578–720)630 (630–720)630 (540–720)
Weekly Kt/V4.08 (3.63–4.40)3.90 (3.60–4.53)4.13 (3.75–4.36)
Dialysis access blood flow, ml/min310 (300–350)300 (288–350)330 (300–350)
Anuric (%)25 (44)13 (45)12 (43)
Urine volume for nonanuric subjects, ml/d1250 (600–1875)1525 (600–1975)925 (525–1750)
Medication (%)
 Calcium carbonate18 (32)9 (31)9 (32)
 Sevelamer40 (70)19 (66)21 (75)
 Lanthanum17 (30)10 (34)7 (25)
 Alfacalcidol40 (70)17 (59)23 (82)
 Cinacalcet14 (25)7 (24)7 (25)
 Intravenous iron32 (56)17 (59)15 (54)
 Erythropoeitin simulating agent50 (88)27 (93)23 (82)
 Warfarin3 (5)3 (10)0 (0)
  • Medians and interquartile ranges are given for continuous values, and absolute numbers and percentages are given for categorical values.